Parkman Healthcare Partners LLC Invests $9.67 Million in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Parkman Healthcare Partners LLC bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 425,000 shares of the company’s stock, valued at approximately $9,669,000. Viridian Therapeutics makes up 1.2% of Parkman Healthcare Partners LLC’s holdings, making the stock its 29th biggest position. Parkman Healthcare Partners LLC owned approximately 0.54% of Viridian Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in VRDN. FMR LLC grew its position in shares of Viridian Therapeutics by 16.8% during the 3rd quarter. FMR LLC now owns 11,183,478 shares of the company’s stock valued at $254,424,000 after buying an additional 1,610,130 shares during the last quarter. Maverick Capital Ltd. lifted its stake in shares of Viridian Therapeutics by 22.9% in the second quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company’s stock worth $43,036,000 after buying an additional 615,531 shares during the last quarter. Vanguard Group Inc. grew its position in Viridian Therapeutics by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after purchasing an additional 233,331 shares during the last quarter. Novo Holdings A S raised its position in Viridian Therapeutics by 19.3% in the third quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock worth $54,259,000 after purchasing an additional 385,000 shares in the last quarter. Finally, Great Point Partners LLC increased its holdings in shares of Viridian Therapeutics by 50.0% during the third quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock worth $17,062,000 after buying an additional 250,000 shares in the last quarter.

Viridian Therapeutics Trading Down 4.3 %

Shares of Viridian Therapeutics stock opened at $20.09 on Wednesday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average price is $22.72 and its 200 day moving average price is $17.50. The firm has a market capitalization of $1.59 billion, a PE ratio of -4.66 and a beta of 1.04. Viridian Therapeutics, Inc. has a twelve month low of $11.40 and a twelve month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on VRDN shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Monday, November 25th. BTIG Research raised their target price on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, September 26th. The Goldman Sachs Group raised their price target on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 target price (down from $31.00) on shares of Viridian Therapeutics in a research report on Monday, August 12th. Finally, HC Wainwright increased their price target on Viridian Therapeutics from $27.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.33.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, COO Thomas W. Beetham purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average cost of $23.41 per share, with a total value of $117,050.00. Following the acquisition, the chief operating officer now directly owns 6,000 shares of the company’s stock, valued at approximately $140,460. This trade represents a 500.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Stephen F. Mahoney purchased 21,400 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the transaction, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 1,626,400 shares of company stock worth $30,616,312 in the last ninety days. 0.65% of the stock is owned by insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.